Three-part educational program for healthcare providers on the effects of cannabis on multiple sclerosis symptoms
The Consortium of Multiple Sclerosis Centers (CMSC), the largest North American multidisciplinary membership organization dedicated to defining and advancing the standard of care of MS patients, announces a new webinar series: Utilizing Cannabis for MS Management: Helping Patients Understand Risks and Benefits. This 3-part educational program is being produced in partnership with NeurologyLive®, a multimedia platform dedicated to providing health care professionals who treat neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology. “Utilizing Cannabis for MS Management” series will take place live on October 14th, October 21st, and October 28th at 7:00 PM EDT.
Specifically designed to engage and inform health care providers about the effects of cannabis on MS symptoms, including pain and spasticity, the featured speaker will be Allen C. Bowling, MD, PhD, Director of the NeuroHealth Institute and Clinical Professor of Neurology at the University of Colorado. He has devoted his career to developing evidence-based information about unconventional and lifestyle medicine and creating models for using this information to provide integrative neurological care of those with MS.
During this webinar, Dr. Bowling will describe the latest information on pharmacology, efficacy, and adverse events–including drug interactions–associated with cannabis use in MS. He will also address current FDA-standards for product licensing and monitoring as well as oversight for products purchased in cannabis dispensaries.
Participants will also learn about the fundamentals of cannabis, available MS clinical trial data regarding impact of cannabis on MS pathophysiology, as well as hear case studies evaluating the risk for interactions between cannabis and disease-modifying therapies used for treatment of MS. Participants will earn 1 CE credit for completing each session.
“With more states legalizing cannabis and MS patients increasingly inquiring about and using it for treatment of MS symptoms, it is important that healthcare providers have the most up to date and evidence-based information on cannabis and its effect on MS,” said June Halper, CEO, CMSC.
“NeurologyLive® is pleased to partner with CMSC on this increasingly relevant topic in MS care,” said Mike Hennessy Jr., President and CEO of MJH Life Sciences™, the parent company of NeurologyLive®.
For more information and to register for the free virtual webinar series, click here.
This activity is supported by an independent educational grant from Greenwich Biosciences.
ABOUT CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS (CMSC)
The CMSC includes a professional network of 13,500 healthcare clinicians and scientists worldwide. Its membership represents the full spectrum of MS healthcare professionals: physicians, nursing professionals, advanced practice clinicians, pharmacists, rehabilitation and mental health professionals, researchers, and patient advocates. The work of the CMSC directly influences the quality of care for hundreds of thousands of people living with MS. For more information visit: http://www.
A multimedia platform for health care professionals treating neurological diseases, NeurologyLive® delivers direct access to practice-changing news and expert insights directly from top medical conferences and researchers to improve the lives of patients with neurological diseases such as dementia and Alzheimer disease, epilepsy, headache and migraine, movement disorders, multiple sclerosis, neuromuscular diseases, sleep disorders and stroke. The NeurologyLive® platform offers an in-depth look at the hundreds of new treatments in development with ever-expanding mechanisms of action, all during an unprecedented time of growing demand for neurology expertise. The NeurologyLive® platform also connects visitors with the most up-to-date clinical trial results, Food and Drug Administration approvals, practice-changing research and expert insights. NeurologyLive® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.
CMSC Media Contact:
NeurologyLive® Media Contact: